Movement Alert｜Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally

Market Focus10:58

On July 2, Hansoh Pharmaceutical rose 6.01% in regular trading, trading at 31.44 HKD/share, with turnover of approximately 205 million HKD.

On the news front, the company announced on June 30 that its innovative drug pemosatide injection received a drug registration certificate, marking the first domestically developed long-acting ESA product to gain approval in China, signaling accelerated commercialization of its innovation pipeline. Concurrently, the broader pharmaceutical sector rallied strongly, with United Lab up 8.78%, Simcere Pharma up 8.02%, and CSPC Pharma up 7.17%.

Catalysts have been released in rapid succession for the company. Its weight-loss drug olatorepatide injection and HS-10568 injection NDA submissions were both accepted by China NMPA in June. Additionally, a 10% share buyback authorization was passed at the annual general meeting on June 26. Multiple institutions maintain Buy ratings with target prices ranging from 40 to 46.41 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189121903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189121903","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally","media":"Market Focus","content":"<p><p>On July 2, Hansoh Pharmaceutical rose 6.01% in regular trading, trading at 31.44 HKD/share, with turnover of approximately 205 million HKD.</p><p>On the news front, the company announced on June 30 that its innovative drug pemosatide injection received a drug registration certificate, marking the first domestically developed long-acting ESA product to gain approval in China, signaling accelerated commercialization of its innovation pipeline. Concurrently, the broader pharmaceutical sector rallied strongly, with United Lab up 8.78%, Simcere Pharma up 8.02%, and CSPC Pharma up 7.17%.</p><p>Catalysts have been released in rapid succession for the company. Its weight-loss drug olatorepatide injection and HS-10568 injection NDA submissions were both accepted by China NMPA in June. Additionally, a 10% share buyback authorization was passed at the annual general meeting on June 26. Multiple institutions maintain Buy ratings with target prices ranging from 40 to 46.41 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 10:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Hansoh Pharmaceutical rose 6.01% in regular trading, trading at 31.44 HKD/share, with turnover of approximately 205 million HKD.</p><p>On the news front, the company announced on June 30 that its innovative drug pemosatide injection received a drug registration certificate, marking the first domestically developed long-acting ESA product to gain approval in China, signaling accelerated commercialization of its innovation pipeline. Concurrently, the broader pharmaceutical sector rallied strongly, with United Lab up 8.78%, Simcere Pharma up 8.02%, and CSPC Pharma up 7.17%.</p><p>Catalysts have been released in rapid succession for the company. Its weight-loss drug olatorepatide injection and HS-10568 injection NDA submissions were both accepted by China NMPA in June. Additionally, a 10% share buyback authorization was passed at the annual general meeting on June 26. Multiple institutions maintain Buy ratings with target prices ranging from 40 to 46.41 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1189121903","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189121903","pubTimestamp":1782961090,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Hansoh Pharmaceutical rose 6.01% in regular trading, trading at 31.44 HKD/share, with turnover of approximately 205 million HKD.On the news front, the company announced on June 30 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"异动快讯|翰森药业常规交易涨6.01%培莫沙肽注射液获批叠加医药板块反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 2, Hansoh Pharmaceutical rose 6.01% in regular trading, trading at 31.44 HKD/share, with turnover of approximately 205 million HKD.On the news front, the company announced on June 30 that its innovative drug pemosatide injection received a drug registration certificate, marking the first domestically developed long-acting ESA product to gain approval in China, signaling accelerated commercialization of its innovation pipeline. Concurrently, the broader pharmaceutical sector rallied strongly, with United Lab up 8.78%, Simcere Pharma up 8.02%, and CSPC Pharma up 7.17%.Catalysts have been released in rapid succession for the company. Its weight-loss drug olatorepatide injection and HS-10568 injection NDA submissions were both accepted by China NMPA in June. Additionally, a 10% share buyback authorization was passed at the annual general meeting on June 26. Multiple institutions maintain Buy ratings with target prices ranging from 40 to 46.41 HKD.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189121903","isCrawlerRequest":true}